238 related articles for article (PubMed ID: 32126254)
1. Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods.
Song L; Yao X; Liu Y; Zhong W; Jiang J; Liu H; Zhou H; Shi C; Zong K; Wang C; Ma C; Liu D; Hu P
Eur J Pharm Sci; 2020 Apr; 147():105281. PubMed ID: 32126254
[TBL] [Abstract][Full Text] [Related]
2. A Model-Informed Approach to Accelerate the Clinical Development of Janagliflozin, an Innovative SGLT2 Inhibitor.
Song L; Wang X; Sun J; Hu X; Li H; Hu P; Liu D
Clin Pharmacokinet; 2023 Mar; 62(3):505-518. PubMed ID: 36802026
[TBL] [Abstract][Full Text] [Related]
3. Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods.
Liu D; Ma X; Liu Y; Zhou H; Shi C; Wu F; Jiang J; Hu P
Eur J Pharm Sci; 2016 Jun; 89():73-82. PubMed ID: 27108678
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium-glucose co-transporter-2 inhibitor, in Chinese people with type 2 diabetes mellitus.
Li X; Zhu X; Liu J; Li Q; Zhang H; Li C; Wu M; Gao L; Wen H; Li X; Tang X; Liu L; Ding Y
Diabetes Obes Metab; 2020 Dec; 22(12):2316-2324. PubMed ID: 32744380
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method.
Song L; Xue J; Zhang J; Li S; Liu D; Zhou T
Eur J Pharm Sci; 2021 Mar; 158():105584. PubMed ID: 33039565
[TBL] [Abstract][Full Text] [Related]
6. A model-based meta analysis study of sodium glucose co-transporter-2 inhibitors.
Yao X; Zhou J; Song L; Ren Y; Hu P; Liu D
CPT Pharmacometrics Syst Pharmacol; 2023 Apr; 12(4):487-499. PubMed ID: 36890732
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology.
Maurer TS; Ghosh A; Haddish-Berhane N; Sawant-Basak A; Boustany-Kari CM; She L; Leininger MT; Zhu T; Tugnait M; Yang X; Kimoto E; Mascitti V; Robinson RP
AAPS J; 2011 Dec; 13(4):576-84. PubMed ID: 21870203
[TBL] [Abstract][Full Text] [Related]
8. Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic model.
Zhao H; Wei Y; He K; Zhao X; Mu H; Wen Q
Eur J Pharm Sci; 2022 Dec; 179():106298. PubMed ID: 36162752
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
Saito M; Kaibara A; Kadokura T; Toyoshima J; Yoshida S; Kazuta K; Ueyama E
Br J Clin Pharmacol; 2019 Aug; 85(8):1808-1819. PubMed ID: 31026084
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Prediction of Human Pharmacokinetics and Pharmacodynamics of CKD519, a Potent Inhibitor of Cholesteryl Ester Transfer Protein (CETP).
Choi S; Han S; Jeon S; Yim DS
Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31311144
[TBL] [Abstract][Full Text] [Related]
12. In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach.
Yamaguchi K; Kato M; Suzuki M; Hagita H; Takada M; Ayabe M; Aso Y; Ishigai M; Ikeda S
J Pharmacol Exp Ther; 2013 Apr; 345(1):52-61. PubMed ID: 23386251
[TBL] [Abstract][Full Text] [Related]
13. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
de Vries Schultink AHM; Doornbos RP; Bakker ABH; Bol K; Throsby M; Geuijen C; Maussang D; Schellens JHM; Beijnen JH; Huitema ADR
Invest New Drugs; 2018 Dec; 36(6):1006-1015. PubMed ID: 29728897
[TBL] [Abstract][Full Text] [Related]
14. Translational PK/PD Modeling of Tumor Growth Inhibition and Target Inhibition to Support Dose Range Selection of the LMP7 Inhibitor M3258 in Relapsed/Refractory Multiple Myeloma.
Lignet F; Esdar C; Walter-Bausch G; Friese-Hamim M; Stinchi S; Drouin E; El Bawab S; Becker AD; Gimmi C; Sanderson MP; Rohdich F
J Pharmacol Exp Ther; 2023 Jan; 384(1):163-172. PubMed ID: 36273822
[TBL] [Abstract][Full Text] [Related]
15. Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration.
Zhang YF; Liu YM; Yu C; Wang YT; Zhan Y; Liu HY; Zou JJ; Jia JY; Chen Q; Zhong DF
Clin Ther; 2021 Feb; 43(2):396-409. PubMed ID: 33454124
[TBL] [Abstract][Full Text] [Related]
16. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus.
Zhang H; Zhu X; Li X; Chen H; Wu M; Li C; Liu J; Liu C; Zhang Y; Ding Y
Diabetes Obes Metab; 2020 Feb; 22(2):191-202. PubMed ID: 31588657
[TBL] [Abstract][Full Text] [Related]
18. Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.
Vugmeyster Y; Rohde C; Perreault M; Gimeno RE; Singh P
MAbs; 2013; 5(3):373-83. PubMed ID: 23529133
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
Yakovleva T; Sokolov V; Chu L; Tang W; Greasley PJ; Peilot Sjögren H; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
Diabetes Obes Metab; 2019 Dec; 21(12):2684-2693. PubMed ID: 31423699
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Wang Y; Lou Y; Wang J; Li D; Chen H; Zheng T; Xia C; Song X; Dong T; Li J; Li J; Liu H
Eur J Med Chem; 2019 Oct; 180():398-416. PubMed ID: 31325786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
